Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Gilead Sciences
(NQ:
GILD
)
119.79
+1.35 (+1.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 31, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
10,030,205
Open
116.06
Bid (Size)
118.71 (1)
Ask (Size)
120.00 (1)
Prev. Close
118.44
Today's Range
114.02 - 121.91
52wk Range
86.08 - 124.61
Shares Outstanding
1,253,809,440
Dividend Yield
2.64%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Amgen Solidifies Biotech Dividend Prowess with $2.38 Q4 2025 Payout
October 31, 2025
Thousand Oaks, CA – October 31, 2025 – Amgen (NASDAQ: AMGN), a leading biotechnology giant, has declared a quarterly dividend of $2.38 per share for the fourth quarter of 2025. This significant...
Via
MarketMinute
Topics
Intellectual Property
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026
October 31, 2025
Gilead beats estimates, raises 2025 guidance, driven by strong HIV and liver drug sales and multiple launches planned for 2026.
Via
Benzinga
Topics
Earnings
Performance
YTD
+30.4%
+30.4%
1 Month
+7.8%
+7.8%
3 Month
+5.8%
+5.8%
6 Month
+15.5%
+15.5%
1 Year
+34.9%
+34.9%
More News
Read More
Gilead GILD Q3 2025 Earnings Call Transcript
October 31, 2025
Via
The Motley Fool
Topics
Earnings
GILD Q3 Deep Dive: HIV and Liver Disease Strength Offset Oncology Headwinds
October 31, 2025
Via
StockStory
Earnings Scheduled For October 30, 2025
October 30, 2025
Via
Benzinga
Gilead Stock Ignites Retail-Trader Frenzy As Trodelvy Cuts Breast Cancer Progression Risk By 38% In Phase 3 Trial
October 20, 2025
Via
Stocktwits
Nasdaq 100 Rebounds, Amazon Jumps 10% On Strong Earnings: What's Moving Markets Friday?
October 31, 2025
Via
Benzinga
Gilead Sciences Wins Prestigious 2025 Prix Galien USA Award for Best Pharmaceutical Product With Yeztugo® (Lenacapavir)
October 31, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Meta Meltdown Sends Nasdaq Tumbling as Apple Shines After Hours
October 31, 2025
Via
Chartmill
Topics
Economy
Is Tango Therapeutics Stock a Buy, Sell, or Hold After Major Shareholder Third Rock Ventures Sold Nearly Half a Million Shares?
October 31, 2025
Via
The Motley Fool
Topics
Regulatory Compliance
Gilead Sciences Inc (NASDAQ:GILD) Reports Mixed Q3 2025 Results with Strong Earnings Beat and Cautious Revenue Outlook
October 30, 2025
Via
Chartmill
Topics
Earnings
Gilead Sciences (NASDAQ:GILD) Exceeds Q3 Expectations
October 30, 2025
Via
StockStory
Covid Continues To Haunt Gilead. How One Drug Dinged Product Sales.
October 30, 2025
Via
Investor's Business Daily
Gilead Sciences Announces Third Quarter 2025 Financial Results
October 30, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
CVS Health Delivers Confident Outlook After Q3 Performance, Stock Hits 52-Week High
October 29, 2025
Via
Benzinga
A Glimpse of Gilead Sciences's Earnings Potential
October 29, 2025
Via
Benzinga
Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday?
October 30, 2025
Via
Benzinga
Topics
Economy
Gilead Sciences (GILD) Reports Q3: Everything You Need To Know Ahead Of Earnings
October 28, 2025
Via
StockStory
Topics
Artificial Intelligence
Market's Perilous Peak: Is the U.S. Stock Market More Overvalued Than Ever?
October 27, 2025
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today
October 27, 2025
Via
Benzinga
Retail Investors' Top Stocks With Earnings This Week: SoFi, Apple, Meta And More
October 27, 2025
Via
Benzinga
3 Value Stocks We Approach with Caution
October 27, 2025
Via
StockStory
Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta
October 23, 2025
From
Gilead Sciences, Inc.
Via
Business Wire
Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence
October 22, 2025
Via
MarketMinute
Biotech Boom: Strategic Realignments and AI Integration Fuel Investor Focus, Signaling Broader Market Shifts
October 19, 2025
Via
MarketMinute
Topics
Artificial Intelligence
ETFs
Economy
Frequently Asked Questions
Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 119.79
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 10/31/25 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 150.19B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 150B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.